Publications scientifiques en 2023

Depuis le 31/03/2025
  1. Adverse drug reaction related to drug shortage: A retrospective study on the French National Pharmacovigilance Database.
    Bourneau-Martin D, Babin M, Grandvuillemin A, Mullet C, Salvo F, Singier A, Cellier M, Fresse A, de Canecaude C, Pietri T, Drablier G, Geniaux H, Lagarce L, Laroche ML, Briet M; French Network of Regional Pharmacovigilance Centres.
    Br J Clin Pharmacol. 2023
  2. Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
    Benaboud S, Solas C, Bouchet S, Gregoire M, Lemaitre F, Venisse N, Lê MP, Muret P, Parant F, Neant N, Boujafaar S, Lagoutte-Renosi J, Garraffo R, Peytavin G.
    J Antimicrob Chemother. 2023
  3. Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany.
    Hyeraci G, Gini R, Bezin J, Iannone LF, Benemei S, Lupi C, De Cesaris F, Geppetti P, Roberto G.
    Headache. 2023
  4. [Analyze and use the results of clinical studies in the perspective of good use. Critical analysis, clinical research and levels of evidence]
    Pariente A, de Germay S.
    Rev Prat. 2023
  5. Drugs and the elderly: A complex interaction.
    Bégaud B, de Germay S, Noize P.
    Therapie. 2023
  6. [Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice]
    de Germay S, Conte C, Micallef J, Bouquet E, Chouchana L, Lafaurie M, Pariente A; au nom du groupe de pharmaco-épidémiologie de la Société Française de Pharmacologie et de Thérapeutique (SFPT).
    Therapie. 2023
  7. Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice.
    de Germay S, Conte C, Micallef J, Bouquet E, Chouchana L, Lafaurie M, Pariente A; Pharmacoepidemiological group of the French Society of Pharmacology and Therapeutics (SFPT).
    Therapie. 2023
  8. Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020.
    Diaz L, Eiden C, Jouanjus E, Frauger E, Fouilhé N, Djezzar S, Gibaja V, Boucher A, Le Boisselier R, Libert F, Caous AS, Monzon E, Guerlais M, Daveluy A, Fauconneau B, Peyrière H.
    Therapie. 2023
  9. Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran).
    Valnet-Rabier MB, Tebacher M, Gautier S, Micallef J, Salvo F, Pariente A, Bagheri H.
    Therapie. 2023
  10. Use of psychotropic drugs in the elderly in France: Are we condemned to remain at high tide?
    Pariente A.
    Therapie. 2023
  11. Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: The French perspective.
    Salvo F, Pariente A, Valnet-Rabier MB, Drici MD, Cholle C, Mathieu C, Singier A, Bagheri H, Tebacher M, Micallef J, Gautier S; French Network of Regional Pharmacovigilance Centers.
    Therapie. 2023
  12. Drug-Drug Interactions and the Risk of Emergency Hospitalizations: A Nationwide Population-Based Study.
    Létinier L, Bezin J, Jarne A, Pariente A.
    Drug Saf. 2023
  13. The ongoing structuring of human papillomavirus (HPV) vaccination in middle schools in Nouvelle-Aquitaine, France.
    Quelet S, Valadeau C, Héron-Rougier C, Pariente A, Gault G, Elleboode B.
    Infect Dis Now. 2023
  14. Response to Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.
    Bezin J, Mathieu C, Faillie JL, Pariente A.
    Diabetes Care. 2023
  15. Nitrous oxide: a unique official French addictovigilance national survey.
    Guerlais M, Aquizerate A, Lionnet A, Daveluy A, Duval M, Gérardin M, Istvan M, Laforgue EJ, Victorri-Vigneau C.
    Front Public Health. 2023
  16. Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase®).
    Duga AL, Salvo F, Kay A, Figueras A.
    Antibiotics (Basel). 2023
  17. Interpretation of Pharmacovigilance Disproportionality Analyses.
    Khouri C, Fusaroli M, Salvo F, Raschi E.
    Clin Pharmacol Ther. 2023
  18. Impact of COVID-19 epidemic on antihypertensive drug treatment disruptions: results from a nationwide interrupted time-series analysis.
    Mathieu C, Bezin J, Pariente A.
    Front Pharmacol. 2023
  19. Why the article that led to the widespread use of hydroxychloroquine in COVID-19 should be retracted.
    Barraud D, Besançon L, Bik EM, Billy E, Clarot F, Frank F, Guihur A, Hajage D, Lacombe K, Maisonneuve H, Molimard M, Mulot M, Samuel A.
    Therapie. 2023
  20. General hospital admissions in young and middle-aged people who use psychoactive substances: Impact of Covid-19 lockdowns.
    Perino J, Ramaroson H, Ong N, Bezin J, Gilleron V, Daveluy A, Tournier M.
    Int J Drug Policy. 2023
  21. Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon.
    Mpoh MM, Deli V, Daniel TT, Salvo F.
    Int J Mycobacteriol. 2023
  22. Risk of suicide attempt and suicide associated with benzodiazepine: A nationwide case crossover study.
    Tournier M, Bénard-Laribière A, Jollant F, Hucteau E, Diop PY, Jarne-Munoz A, Pariente A, Oger E, Bezin J.
    Acta Psychiatr Scand. 2023
  23. [Increase of overdose and deaths related to methadone during COVID-19 epidemic in 2020]
    Frauger E, Fouilhé N, Lacroix C, Daveluy A, Le Boisselier R, Bertin C, Revol B, Carton L, Chevalier C, Eiden C, Gibaja V, Aquizerate A, Chaouachi L, Bouquet E, Roussin A, Mallaret M, Micallef J.
    Therapie. 2023
  24. Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study.
    Fusaroli M, Salvo F, Bernardeau C, Idris M, Dolladille C, Pariente A, Poluzzi E, Raschi E, Khouri C.
    Drug Saf. 2023
  25. Will the future of pharmacovigilance be more automated?
    Salvo F, Micallef J, Lahouegue A, Chouchana L, Létinier L, Faillie JL, Pariente A.
    Expert Opin Drug Saf. 2023
  26. Bleeding risk with concurrent use of anticoagulants and ibrutinib: A population-based nested case-control study.
    Allouchery M, Tomowiak C, Singier A, Puyade M, Dari L, Pambrun E, Pariente A, Bezin J, Pérault-Pochat MC, Salvo F.
    Br J Haematol. 2023
  27. Use of Bisphosphonates and the Risk of Skin Ulcer: A National Cohort Study Using Data from the French Health Care Claims Database.
    Jambon-Barbara C, Bernardeau C, Bezin J, Roustit M, Blaise S, Cracowski JL, Khouri C.
    Drug Saf. 2023
  28. Trajectories of Benzodiazepine Use among Older Adults from a Concordance-with-Guidelines Perspective: A Nationwide Cohort Study.
    Maumus-Robert S, Jarne-Munoz A, Tournier M, Bégaud B, Pariente A.
    Drugs Aging. 2023
  29. Increase in hospitalisation-associated methadone intoxication in France following first COVID-19 lockdown.
    Perino J, Demourgues M, Ramaroson H, Bezin J, Micallef J, Miremont-Salamé G, Frauger E, Gilleron V, Ong N, Daveluy A.
    Public Health. 2023
  30. Letter to the Editor: The Cannabinoid Consumed Is Not Necessarily the One Expected: Recent Experience with Hexahydrocannabinol.
    Guyon J, Paradis C, Titier K, Braganca C, Peyre A, Nardon A, Daveluy A, Molimard M, Labadie M, Castaing N.
    Cannabis Cannabinoid Res. 2023
  31. Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer.
    Gouverneur A, Favary C, Jové J, Rouyer M, Bignon E, Salvo F, Tchalla A, Paillaud E, Aparicio T, Noize P.
    Target Oncol. 2023
  32. Dual Orexin Receptor Antagonists and Suicide Risk: Findings From the WHO Spontaneous Reporting Database.
    Salvo F, Micoulaud-Franchi JA, Palagini L, Geoffroy PA.
    J Clin Psychiatry. 2023
  33. Factors associated with internal contamination of nurses by antineoplastic drugs based on biomonitoring data from a previous study.
    Villa A, Geshkovska A, Bellagamba G, Baldi I, Molimard M, Verdun-Esquer C, Lehucher-Michel MP, Canal-Raffin M.
    Int J Hyg Environ Health. 2023
  34. Statin treatment is not associated with an increased risk of adrenal insufficiency in real-world setting.
    Maumus-Robert S, Jarne-Munoz A, Pariente A, Duroux T, Duranteau L, Bezin J.
    Front Endocrinol (Lausanne). 2023
  35. Analgesic switching in chronic users of dextropropoxyphene in France.
    Daveluy A, Bryan MC, Miremont-Salamé G, Lassalle R, Lacueille C, Grelaud A, Floccia M, Haramburu F, Lapeyre-Mestre M, Micallef J, Salvo F.
    Fundam Clin Pharmacol. 2023
  36. Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase.
    Calapai F, Mannucci C, McQuain L, Salvo F.
    Pharmaceuticals (Basel). 2023
  37. Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
    de Germay S, Singier A, Salvo F, Pariente A; French Pharmacovigilance Network.
    Drug Saf. 2023
  38. Real-world effect of iloprost in patients with chronic limb-threatening ischemia (CLTI): A cohort study.
    Loubna D, Constans J, Boulon C, Caradu C, Lapébie FX, Bura-Rivière A, Chastaingt L, Lacroix P, Bezin J, Pariente A.
    Vasc Med. 2023
  39. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study.
    Allouchery M, Brunet K, Tomowiak C, Singier A, Pambrun E, Pariente A, Bezin J, Pérault-Pochat MC, Salvo F.
    Mycoses. 2023
  40. Quelles actions pour lutter contre la désinformation sur les produits de santé ?
    Micallef J, Maisonneuve H, Muller S, Molimard M, Bégaud B, Cabut S, Daban M, Drici MD, Gatignol C, Grumblat A, Guaspare-Cartron C, Lasserre B, Mebarki A, Pons C, Prabonnaud F, Raynaud C, Saint-Lary O.
    Therapie. 2023
  41. Cost-effectiveness of screening of coronary artery disease in patients with type 2 diabetes at a very high cardiovascular risk (SCADIAB) study. Updated study design: emulation of a randomised target trial using electronic health records.
    Mohammedi K, Cordon A, Rigalleau V, Foussard N, Bairras-Martin C, Couffinhal T, Bezin J, Benard A.
    Cardiovasc Diabetol. 2023
  42. Effects of iloprost in patients with critical limb ischemia: Results of a cohort study from the COPART registry.
    Dari L, Constans J, Boulon C, Caradu C, Labépie FX, Bura-Rivière A, Chastaingt L, Lacroix P, Bezin J, Pariente A.
    J Med Vasc. 2023
  43. Psychoactive substance intoxication leading to general hospital admission in young and middle-aged people during and after the first lockdown.
    Perino J, Ramaroson H, Ong N, Lancelot V, Bezin J, Gilleron V, Daveluy A, Tournier M.
    Therapie. 2023
  44. A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort.
    Devillier P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Demoly P.
    Expert Rev Clin Immunol. 2023
  45. What should be done to combat misinformation about health products?
    Micallef J, Maisonneuve H, Muller S, Molimard M, Bégaud B, Cabut S, Daban M, Drici MD, Gatignol C, Grumblat A, Guaspare-Cartron C, Lasserre B, Mebarki A, Pons C, Prabonnaud F, Raynaud C, Saint-Lary O.
    Therapie. 2023